Antimicrobial Susceptibility Testing Market by Product Type (Manual Products, Automated Products and Consumables), By Method Type (ETEST, Disks Diffusion, Rapid Automation Method and Other), and End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030
- ALL4676862
- 273 Pages
- September 2021
- Diagnostic and Biotech
When microbes such as bacteria and fungi are unable to survive in the presence of one or more antimicrobial drugs, this is referred to as susceptibility. Susceptibility testing is done on bacteria, fungi, virus that cause an individual's infection after they have been retrieved in a specimen culture. Testing is performed to assess the potential efficacy of certain antibiotics on bacteria and/or if bacteria have evolved resistance to certain antibiotics, and is similarly done for antifungal and antiviral species. The outcomes of this test can be used to assist for selecting the drug(s) that are most likely to be effective in treating an infection. They have the ability to acquire antibiotic, antifungal and antiviral resistance at any time. Drugs that were formerly used to kill or limit their growth may no longer be effective.
According to World Health Organization (WHO) in 2019, Every year, 700,000 people die as a result of drug-resistant illnesses, including 230,000 from multidrug-resistant tuberculosis. More prevalent diseases, such as respiratory tract infections, sexually transmitted infections, and urinary tract infections, are becoming incurable; lifesaving medical operations are getting more dangerous; and our food systems are becoming increasingly unstable. In addition, UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance anticipated that by 2050, drug-resistant diseases might kill 10 million people each year and by 2030, antimicrobial resistance might push up to 24 million people into extreme poverty.
The growth of the global antimicrobial susceptibility testing market is majorly driven by the increase in prevalence of infectious diseases, as well as epidemic and pandemic occurrences, rapidly expanding geriatric population that leads to rise in chronic diseases, rising awareness programs and initiatives for personalized treatment has a positive impact on the market growth. Furthermore, increased usage of the antimicrobial susceptibility testing by the pharmaceutical firms plays a major role in propelling the antimicrobial susceptibility testing market forward.
Because of the upsurge in major infectious illnesses, the demand for clinical microbiology testing procedures has also been steadily increasing in recent years. The growing worldwide burden of infectious illnesses will certainly boost demand for clinical microbiology methods for microbial identification and antibiotic susceptibility testing against pathogens. This will give a chance to produce an increasing number of microbiological products to support ongoing research investigations and fulfil the global need for effective and accurate disease diagnostic tools.
In addition, rising government initiatives to build high-quality hospital infrastructure at the same time rising infectious diseases. Antimicrobial susceptibility test kits are gaining popularity in the institutes, pharmaceutical and biotechnology industries for the study and development of novel antimicrobial medicines. Furthermore, rising incidences of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza, and other diseases globally is anticipated to result in increased usage of antimicrobial susceptibility testing to decrease resistance exposure. In July 2020, Cepheid, a Danaher subsidiary and The Foundation for Innovative New Diagnostics (FIND) announced the release of the new Xpert MTB/XDR test, which allows for extended drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can help doctors swiftly prescribe treatment regimens for extensively drug-resistant tuberculosis (XDR-TB).
On the contrary, the cost of the automated identification system of antimicrobial susceptibility testing (ID/AST systems) is highly expensive. Automated research tools for antimicrobial susceptibility are equipped with cutting-edge features and capabilities and are priced accordingly. Furthermore, stringent government regulations are expected to restrain the market. Thus, advancements in technology in the healthcare sector and rise in prevalence of antibiotic resistance due to overuse of broad spectrum antibiotic are expected to propel the growth of the market.
Awareness initiatives for antimicrobial resistance and its control by the government. Increasing expenditure in the healthcare sector, are expected to boost the market. Accordingly, in June 2021, The Biomedical Advanced Research and Development Authority (BARDA) had granted Selux Diagnostics Inc., an additional $14.6 million in funding for their next-generation phenotyping (NGP) technology for fast antimicrobial susceptibility testing (AST).
Emerging markets and significant R&D to develop efficient antimicrobial susceptibility testing, innovation of various automated systems, susceptibility disks, susceptibility plates, minimum inhibitory concentration (MIC) strips and others are projected to provide substantial growth opportunities for key players in antimicrobial susceptibility testing market.
The global antimicrobial susceptibility testing market is segmented onto the basis of product type, method type, end user and region. On the basis of product type, the market is categorized into manual products, automated products and consumables. By method type the market is categorized into ETEST (Epsilometer test), disks diffusion, rapid automation method and others. By end user the market is categorized into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global antimicrobial susceptibility testing market are Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux SA, Bio-Rad Laboratories, Inc., Bruker, Danaher Corporation (Beckman Coulter), F. Hoffmann-La Roche AG, HiMedia Laboratories, Merck KGaA (MilliporeSigma), Thermo Fisher Scientific.
KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global antimicrobial susceptibility testing market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region- & country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Product Type
o Manual Products
o Consumables
o Automated Products
By Method Type
o ETEST
o Disks Diffusion
o Rapid Automation Method
o Others
By End User
o Hospitals & Diagnostic Laboratories
o Pharmaceutical & Biotechnology Companies
o Others
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
KEY MARKET PLAYERS
• Accelerate Diagnostics, Inc.
• Becton, Dickinson and Company,
• Biomerieux SA,
• Bio-Rad Laboratories, Inc.,
• Bruker,
• Danaher Corporation (Beckman Coulter),
• F. Hoffmann-La Roche AG,
• HiMedia Laboratories,
• Merck KGaA (MilliporeSigma),
• Thermo Fisher Scientific
1.1.Report description
Key benefits for stakeholders
1.2.Key market segments
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rising incidence of infectious diseases coupled with epidemic & pandemic occurrences
3.5.1.2.Increasing adoption of antimicrobial susceptibility testing
3.5.1.3.Development of Manual and Automated Products
3.5.2.Restraint
3.5.2.1.High cost of automated AST systems & stringent government regulations
3.5.3.Opportunity
3.5.3.1.Awareness initiatives for antimicrobial resistance and its control
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the antimicrobial susceptibility testing market
CHAPTER 4:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Manual Products
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market analysis, by end user
4.3.Automated Products
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.3.4.Market analysis, by end user
4.4.Consumables
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.4.4.Market analysis, by end user
CHAPTER 5:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.ETEST
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Disks Diffusion
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Rapid Automation Method
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Others
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
CHAPTER 6:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals & Diagnostic Laboratories
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Pharmaceutical & Biotechnology Companies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Others
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America Antimicrobial susceptibility testing market, by Product Type
7.2.3.North America Antimicrobial susceptibility testing market, by Method Type
7.2.4.North America Antimicrobial susceptibility testing market, by End User
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. Antimicrobial susceptibility testing market, by Product Type
7.2.5.1.2.U.S. Antimicrobial susceptibility testing market, by Method Type
7.2.5.1.3.U.S. Antimicrobial susceptibility testing market, by End User
7.2.5.2.Canada
7.2.5.2.1.Canada Antimicrobial susceptibility testing market, by Product Type
7.2.5.2.2.Canada Antimicrobial susceptibility testing market, by Method Type
7.2.5.2.3.Canada Antimicrobial susceptibility testing market, by End User
7.2.5.3.Mexico
7.2.5.3.1.Mexico Antimicrobial susceptibility testing market, by Product Type
7.2.5.3.2.Mexico Antimicrobial susceptibility testing market, by Method Type
7.2.5.3.3.Mexico Antimicrobial susceptibility testing market, by End User
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe Antimicrobial susceptibility testing market, by Product Type
7.3.3.Europe Antimicrobial susceptibility testing market, by Method Type
7.3.4.Europe Antimicrobial susceptibility testing market, by End User
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany Antimicrobial susceptibility testing market, by Product Type
7.3.5.1.2.Germany Antimicrobial susceptibility testing market, by Method Type
7.3.5.1.3.Germany Antimicrobial susceptibility testing market, by End User
7.3.5.2.France
7.3.5.2.1.France Antimicrobial susceptibility testing market, by Product Type
7.3.5.2.2.France Antimicrobial susceptibility testing market, by Method Type
7.3.5.2.3.France Antimicrobial susceptibility testing market, by End User
7.3.5.3.UK
7.3.5.3.1.UK Antimicrobial susceptibility testing market, by Product Type
7.3.5.3.2.UK Antimicrobial susceptibility testing market, by Method Type
7.3.5.3.3.UK Antimicrobial susceptibility testing market, by End User
7.3.5.4.Italy
7.3.5.4.1.Italy Antimicrobial susceptibility testing market, by Product Type
7.3.5.4.2.Italy Antimicrobial susceptibility testing market, by Method Type
7.3.5.4.3.Italy Antimicrobial susceptibility testing market, by End User
7.3.5.5.Spain
7.3.5.5.1.Spain Antimicrobial susceptibility testing market, by Product Type
7.3.5.5.2.Spain Antimicrobial susceptibility testing market, by Method Type
7.3.5.5.3.Spain Antimicrobial susceptibility testing market, by End User
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe Antimicrobial susceptibility testing market, by Product Type
7.3.5.6.2.Rest of Europe Antimicrobial susceptibility testing market, by Method Type
7.3.5.6.3.Rest of Europe Antimicrobial susceptibility testing market, by End User
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Antimicrobial susceptibility testing market, by Product Type
7.4.3.Asia-Pacific Antimicrobial susceptibility testing market, by Method Type
7.4.4.Asia-Pacific Antimicrobial susceptibility testing market, by End User
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan Antimicrobial susceptibility testing market, by Product Type
7.4.5.1.2.Japan Antimicrobial susceptibility testing market, by Method Type
7.4.5.1.3.Japan Antimicrobial susceptibility testing market, by End User
7.4.5.2.China
7.4.5.2.1.China Antimicrobial susceptibility testing market, by Product Type
7.4.5.2.2.China Antimicrobial susceptibility testing market, by Method Type
7.4.5.2.3.China Antimicrobial susceptibility testing market, by End User
7.4.5.3.Australia
7.4.5.3.1.Australia Antimicrobial susceptibility testing market, by Product Type
7.4.5.3.2.Australia Antimicrobial susceptibility testing market, by Method Type
7.4.5.3.3.Australia Antimicrobial susceptibility testing market, by End User
7.4.5.4.India
7.4.5.4.1.India Antimicrobial susceptibility testing market, by Product Type
7.4.5.4.2.India Antimicrobial susceptibility testing market, by Method Type
7.4.5.4.3.India Antimicrobial susceptibility testing market, by End User
7.4.5.5.South Korea
7.4.5.5.1.South Korea Antimicrobial susceptibility testing market, by Product Type
7.4.5.5.2.South Korea Antimicrobial susceptibility testing market, by Method Type
7.4.5.5.3.South Korea Antimicrobial susceptibility testing market, by End User
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific Antimicrobial susceptibility testing market, by Product Type
7.4.5.6.2.Rest of Asia-Pacific Antimicrobial susceptibility testing market, by Method Type
7.4.5.6.3.Rest of Asia-Pacific Antimicrobial susceptibility testing market, by End User
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA Antimicrobial susceptibility testing market, by Product Type
7.5.3.LAMEA Antimicrobial susceptibility testing market, by Method Type
7.5.4.LAMEA Antimicrobial susceptibility testing market, by End User
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil Antimicrobial susceptibility testing market, by Product Type
7.5.5.1.2.Brazil Antimicrobial susceptibility testing market, by Method Type
7.5.5.1.3.Brazil Antimicrobial susceptibility testing market, by End User
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia Antimicrobial susceptibility testing market, by Product Type
7.5.5.2.2.Saudi Arabia Antimicrobial susceptibility testing market, by Method Type
7.5.5.2.3.Saudi Arabia Antimicrobial susceptibility testing market, by End User
7.5.5.3.South Africa
7.5.5.3.1.South Africa Antimicrobial susceptibility testing market, by Product Type
7.5.5.3.2.South Africa Antimicrobial susceptibility testing market, by Method Type
7.5.5.3.3.South Africa Antimicrobial susceptibility testing market, by End User
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA Antimicrobial susceptibility testing market, by Product Type
7.5.5.4.2.Rest of LAMEA Antimicrobial susceptibility testing market, by Method Type
7.5.5.4.3.Rest of LAMEA Antimicrobial susceptibility testing market, by End User
CHAPTER 8:COMPANY PROFILES
8.1.ACCELERATE DIAGNOSTICS, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BECTON, DICKINSON, AND COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.BIO-RAD LABORATORIES, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.BRUKER CORPORATION
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.COMPAGNIE MERIEUX ALLIANCE SAS (BIOMERIEUX S.A.)
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.DANAHER CORPORATION (BECKMAN COULTER INC.)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.F. HOFFMANN-LA ROCHE AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.HIMEDIA LABORATORIES
8.8.1.Company overview
8.8.2.Operating business segments
8.8.3.Product portfolio
8.9.MERCK KGAA (MILLIPORE SIGMA)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
TABLE 01.GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 02.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR MANUAL PRODUCTS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR MANUAL PRODUCTS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 04.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AUTOMATED PRODUCTS, BY REGION, 2020-2030 ($MILLION)
TABLE 05.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AUTOMATED PRODUCTS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 06.CONSUMABLES SUSCEPTIBILITY TESTING MARKET FOR ANTIMICROBIAL, BY REGION, 2020-2030 ($MILLION)
TABLE 07.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONSUMABLES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 08.GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 09.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST, BY REGION, 2020-2030 ($MILLION)
TABLE 10.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISKS DIFFUSION, BY REGION, 2020-2030 ($MILLION)
TABLE 11.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RAPID AUTOMATION METHOD, BY REGION, 2020-2030 ($MILLION)
TABLE 12.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2020-2030 ($MILLION)
TABLE 15.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2030 ($MILLION)
TABLE 16.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 17.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 22.U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 23.U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 24.U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 25.CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 26.CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 27.CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 28.MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 29.MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 30.MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 32.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 33.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 35.GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 36.GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 37.GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 38.FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 39.FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 40.FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 41.UK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 42.UK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 43.UK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 44.ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 45.ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 46.ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47.SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 48.SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 49.SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 50.REST OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 52.REST OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 57.JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 58.JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 59.JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 60.CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 61.CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 62.CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 63.AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 65.AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 66.INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 67.INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 68.INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 71.SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 76.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 77.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 79.BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 80.BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 81.BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 82.SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 84.SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 85.SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 87.SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 88.REST OF LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 90.REST OF LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 91.ACCELERATE: COMPANY SNAPSHOT
TABLE 92.ACCELERATE: OPERATING SEGMENT
TABLE 93.ACCELERATE: PRODUCT PORTFOLIO
TABLE 94.ACCELERATE: KEY DEVELOPMENTS
TABLE 95.BD: COMPANY SNAPSHOT
TABLE 96.BD: OPERATING SEGMENTS
TABLE 97.BD: PRODUCT PORTFOLIO
TABLE 98.BD: KEY DEVELOPMENTS
TABLE 99.BIORAD: COMPANY SNAPSHOT
TABLE 100.BIORAD: OPERATING SEGMENTS
TABLE 101.BIORAD: PRODUCT PORTFOLIO
TABLE 102.BRUKER: SNAPSHOT
TABLE 103.BRUKER: OPERATING SEGMENTS
TABLE 104.BRUKER: PRODUCT PORTFOLIO
TABLE 105.COMPAGNIE: COMPANY SNAPSHOT
TABLE 106.COMPAGNIE: OPERATING SEGMENT
TABLE 107.COMPAGNIE: PRODUCT PORTFOLIO
TABLE 108.COMPAGNIE: KEY DEVELOPMENTS
TABLE 109.DANAHER: COMPANY SNAPSHOT
TABLE 110.DANAHER: PRODUCT SEGMENTS
TABLE 111.DANAHER: PRODUCT PORTFOLIO
TABLE 112.DANAHER: KEY DEVELOPMENTS
TABLE 113.ROCHE: COMPANY SNAPSHOT
TABLE 114.ROCHE: PRODUCT SEGMENTS
TABLE 115.ROCHE: PRODUCT PORTFOLIO
TABLE 116.ROCHE: KEY DEVELOPMENTS
TABLE 117.HIMEDIA: COMPANY SNAPSHOT
TABLE 118.HIMEDIA: OPERATING SEGMENTS
TABLE 119.HIMEDIA: PRODUCT PORTFOLIO
TABLE 120.MERCK: COMPANY SNAPSHOT
TABLE 121.MERCK: OPERATING SEGMENTS
TABLE 122.MERCK: PRODUCT PORTFOLIO
TABLE 123.THERMO FISHER: COMPANY SNAPSHOT
TABLE 124.THERMO FISHER: OPERATING SEGMENTS
TABLE 125.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 126.THERMOFISHER: KEY DEVELOPMENTS
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
